GPI-T-based activation and resulting localization of the receptor into the cellular plasma membrane could ultimately induce the crucial functionality of FR1 and its potential use as a target receptor for the transfer of therapeutics into cancer cells. The gene discussed is TBXT; the disease is cancer.